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ABSTRACT
Pulmonary infiltrates in immunocompromised children often pose problems in terms of deciding on
further diagnostic and therapeutic procedures, but few studies have evaluated the value of non-invasive
and invasive diagnostic methods in paediatric populations. Both galactomannan ELISA and PCR
protocols appear to be less useful in children than in adults. Invasive procedures, such as
bronchoalveolar lavage or lung biopsy, can yield a pathohistological diagnosis and ⁄ or the isolation of
a pathogen. Prospective studies in paediatric patients are needed urgently to assess the value of different
diagnostic procedures and to define an effective and safe diagnostic strategy for the individual child.
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Pulmonary infiltrates revealed by conventional
chest roentgenograms or computerised tomogra-
phy (CT) scans often pose problems in terms of
deciding on further diagnostic and therapeutic
procedures, particularly in immunocompromised
children [1]. Differential diagnoses include infec-
tions caused by a variety of bacteria and fungi,
metastases of an underlying malignancy, or
lesions induced by previous therapy [2,3]; how-
ever, a precise diagnosis is essential for an
appropriate therapeutic approach. In a survey of
27 paediatric cancer centres, we found that non-
invasive and invasive diagnostic procedures were
performed regularly in immunocompromised
children with pulmonary infiltrates by only 18
and nine centres, respectively. Reasons given for
the low usage of these procedures included the
risk of adverse events with invasive modalities,
and the high sensitivity and specificity of imaging
studies. However, a retrospective radiological
study [4] of 27 children with documented asper-
gillosis failed to find a halo-sign indicative of
invasive aspergillosis, but documented various
other findings, including segmental and multilo-
bar consolidation, perihilar infiltrates, multiple
small nodules and larger peripheral nodular
masses. This might reflect the relatively late stage
of disease during which the patients were
scanned, since the halo-sign is seen in up to
75% of adult patients within the first 96 h,
compared with only 20% of adult patients on
day 14 [5]. It has been suggested that there is a
spectrum of radiological disease presentations in
paediatric patients with pulmonary aspergillosis
that is related directly to age [6]. Importantly, CT
scans of immunocompromised children with fun-
gal disease may mimic a variety of diseases,
including malignant tumour [3]. To date, no study
has evaluated the value of magnetic resonance
imaging (MRI) in children with cancer. This
method does not expose the patient to radiation,
but is hampered by the need for sedation of
young children. Similarly, the role of 18F-fluo-
rodeoxyglucose (FDG) positron emission tomo-
graphy (PET) as a diagnostic tool to detect
infection in patients with cancer is unclear [7].
In patients with pulmonary infiltrates, a caus-
ative pathogen can rarely be isolated from blood
cultures [8,9]. In recent years, progress has been
made in the development and evaluation of
non-invasive diagnostic assays for the detection
of bacterial or fungal antigens and genomic DNA
sequences [9]. An ELISA detecting galactoman-
nan (GM), a component of the Aspergillus cell wall
[10], can be used with samples such as blood,
cerebrospinal and bronchial fluid, but the sensi-
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tivity and specificity of this test vary considerably
according to the patient population and the cut-
off level used [11,12]. A study of 3294 serum
samples from 797 episodes, of which 153 had been
classified previously as invasive aspergillosis (31
definite, 67 probable, 55 possible) [11], found that
the manufacturer’s recommendation of a positive
cut-off level of >1.5 resulted in sensitivities of
64.5%, 16.4% and 25.5% in definite, probable and
possible episodes of invasive aspergillosis,
respectively. The overall specificity was 94.8%,
but this was significantly lower (47.6%;
p < 0.0001) for the 42 children analysed. This
might reflect the predominantly milk-based diet
of children, as GM is present in milk and may
translocate across an intestinal wall that has been
damaged by chemotherapy-induced mucositis.
Furthermore, lipoglycan from Bifidobacterium bifi-
dum [13], as well as drugs of fungal origin, e.g.,
piperacillin-tazobactam, may cause elevated GM
levels [14]. On the other hand, anti-Aspergillus
antibodies [11], or the use of antifungal prophy-
laxis or empirical treatment [12], may cause false-
negative results.
PCR offers the potential for rapid and sensitive
diagnosis of invasive fungal infection, and might
allow quantification of fungal loads. In an animal
model of invasive pulmonary aspergillosis, 15 of
60 blood samples yielded a positive PCR result,
but no pathogen could be isolated from the blood
culture [15]. There are various different PCR
protocols, but a commercially available PCR
assay is still lacking. In addition, there are
problems in knowing how to interpret PCR-
positive culture-negative results, which could
reflect either contamination or sub-clinical infec-
tion masked by empirical therapy or neutrophil
recovery. A retrospective study of 20 children and
21 adults with invasive aspergillosis suggested
that a serum-based Taqman real-time PCR assay
was more specific than GM ELISA, and that a
combination of the two could improve the accu-
racy of the diagnosis [16]. It remained unclear
why the sensitivity of the PCR was lower in
children compared with adults.
In contrast to serological and molecular meth-
ods, invasive modalities such as bronchoalveolar
lavage (BAL) or biopsy can yield a pathohisto-
logical diagnosis and ⁄ or the isolation of a patho-
gen. In a study of 53 children with cancer, BAL
was performed because of fever and ⁄ or abnor-
malities seen on chest radiograph. A pathogen
was isolated from 15 of these 53 children, and
malignant cells were found in one patient; how-
ever, minor complications related to the diagnos-
tic procedure occurred with 16 patients [17].
Concomitant to BAL, trans-bronchial biopsy
(TBB) can be performed during bronchoscopy,
even in very small children if special techniques
are used [18]. Complications such as pneumotho-
rax or bleeding are rare. A study using TBB
reported an overall complication rate of 2%
among 84 paediatric patients [19]. All complica-
tions occurred with patients in whom biopsies
were performed with adult forceps. Unfortu-
nately, use of the smaller bronchoscope forceps
resulted in a lower yield of adequate tissue
compared with the adult biopsy forceps (85%
vs. 95%) [19]. As an alternative, trans-thoracal
bronchoscopy (TTB) might be an accurate and
safe option in children with small pulmonary
nodules [20,21]. Cahill et al. [21] described 64
paediatric patients who underwent TTB, mostly
for suspected malignancy (n = 24) or infection
(n = 36). The overall diagnostic yield was 91%,
and only one patient suffered from tension pneu-
mothorax. Importantly, serological and molecular
methods can also be used with specimens
obtained by invasive procedures. For example,
PCR assays detecting fungal infection have been
used successfully with BAL specimens obtained
from patients with pulmonary aspergillosis [22],
but there is an absence of definitive data for
paediatric patients.
Whereas TBB and TTB are hampered by small
sample volumes, especially with children, open
lung biopsy (OLB) can reveal typical macroscopic
changes, and may provide adequate tissue sam-
ples for pathological examination and the culture
of pathogens. Disadvantages are the need for
general anaesthesia and the risk of bleeding. An
analysis of 17 immunocompromised children
revealed that OLB yielded the correct diagnosis
with nine patients for whom examination of
blood, sputum and BAL had not been informative
[23]. If OLB is being considered, it should not be
delayed, as morbidity and mortality rates are
significantly lower for children without respirat-
ory failure, compared with children with respir-
atory failure (14% and 0% vs. 65% and 38%,
respectively) [24].
Although it is unclear whether greater diag-
nostic accuracy improves the overall outcome, a
better diagnostic approach might ultimately
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improve therapeutic strategies, including the
development of new drugs and immunothera-
peutic approaches. However, even invasive diag-
nostic procedures seem to be associated with a
low incidence of adverse events, and there has to
be a balance between the risk of complications
and the benefits of improved diagnosis. To this
end, prospective studies are required urgently in
paediatric patients to assess the value of the
different diagnostic procedures and to define a
safe and cost-effective diagnostic strategy for the
individual patient.
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